Stay updated with breaking news from Pascal Nigen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
ZURICH, SWITZERLAND / ACCESSWIRE / June 6, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP),(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery
Press release content from Accesswire. The AP news staff was not involved in its creation.
60-patient enrollment target met plus 12% over-enrollment; top-line Phase 2a results expected to be presented during the European Sleep Research Society Congress in September 2022Nearly 90% of patients
Since the interim results were released in March, patient enrollment has nearly doubledOf the 60 patients planned for the study, 54 have now been randomized with several others currently undergoing screeningNearly
ZURICH, SWITZERLAND / ACCESSWIRE / April 22, 2022 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development